X8de42096.ef3e.4864.8ee1.2ee7672c1c82
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- MYOGENESIS+0.380
- WNT_BETA_CATENIN_SIGNALING+0.250
- ANGIOGENESIS+0.230
- HEDGEHOG_SIGNALING+0.210
- APICAL_JUNCTION+0.180
- NOTCH_SIGNALING+0.180
- MITOTIC_SPINDLE+0.160
- KRAS_SIGNALING_DN+0.130
- SPERMATOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- MYC_TARGETS_V2-0.510
- INTERFERON_GAMMA_RESPONSE-0.490
- MYC_TARGETS_V1-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.460
- PROTEIN_SECRETION-0.420
- OXIDATIVE_PHOSPHORYLATION-0.410
- UV_RESPONSE_UP-0.390
- E2F_TARGETS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9RC-01A-11R-A38B-07 | — | — | 0.885 |
| 2 | SRR1313107 | — | F | 0.885 |
| 3 | c848ccf8-14d9-4fbd-8366-d4e4ab4dc2e5 | — | — | 0.873 |
| 4 | TCGA-XF-AAMY-01A-11R-A42T-07 | — | — | 0.870 |
| 5 | a545f8c1-39e3-48cc-8c22-897c5d3a21ea | — | — | 0.869 |
| 6 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.869 |
| 7 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.859 |
| 8 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.856 |
| 9 | BS_YK6VQ9SJ | DNET | — | 0.855 |
| 10 | MBCProject_0044_T1_RNA | — | A | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |